COMPARATIVE INCOME STATEMENT		3rd Qtr Ending: 05/31/2005				9 Months Ending: 05/31/2005
		Amounts in Millions		Favorable/Unfavorable		Amounts in Millions		Favorable/Unfavorable
PRELIMINARY		This Year	Last Year	Amount	Pct	This Year	Last Year	Amount	Pct
Net Sales		10,830.6	9,578.5	1,252.1	13.1%	31,706.7	28,081.5	3,625.2	12.9%
Costs and Deductions
	Cost of Sales	7,814.4	7,000.7	-813.7	-11.6%	22,852.0	20,498.0	-2,354.0	-11.5%
	Selling, Occupancy & Admin [3]	2,378.7	2,036.8	-341.9	-16.8%	6,955.2	5,969.0	-986.2	-16.5%
Operating Income		637.5	541.0	96.5	17.8%	1,899.5	1,614.5	285.0	17.7%
	Net Other, Income(Expense)[1][2]	17.5	6.6	10.9	165.2%	49.0	26.1	22.9	87.7%
Earnings Before Taxes		655.0	547.6	107.4	19.6%	1,948.5	1,640.6	307.9	18.8%
	Income Taxes	244.0	205.3	-38.7	-18.9%	718.0	615.2	-102.8	-16.7%
Earnings After Taxes		411.0	342.3	68.7	20.1%	1,230.5	1,025.4	205.1	20.0%
[1]	2004 Drug antitrust litigation settlements: 2nd Qtr - (2 Totaling) $12.7; 3rd Qtr - $3.0; 4th Qtr - $0.6
[2]	2005 Drug antitrust litigation settlements: 1st Qtr - $15.0; 2nd Qtr - $4.7; 3rd Qtr - $6.6
[3]	Prior period amounts have been restated for the accounting of leases consistent with our March 21st, 2005 press release and 8-K.
Earnings Per Share - Basic [3]		$ 0.41	$ 0.33	$ 0.08	24.2%	$ 1.21	$ 1.00	$ 0.21	21.0%
	Before Drug Litigation	$ 0.40	$ 0.33	$ 0.07	21.2%	$ 1.19	$ 0.99	$ 0.20	20.2%
Earnings Per Share - Diluted [3]		$ 0.40	$ 0.33	$ 0.07	21.2%	$ 1.20	$ 0.99	$ 0.21	21.2%
	Before Drug Litigation	$ 0.40	$ 0.33	$ 0.07	21.2%	$ 1.18	$ 0.98	$ 0.20	20.4%
Dividends Per Share		$ 0.05250	$ 0.04313	$ 0.00937	21.7%	$ 0.15750	$ 0.12938	$ 0.02812	21.7%
Weighted Avg Shares Basic		1,019.5	1,023.3			1,021.2	1,024.2
Weighted Avg Shares Diluted		1,029.1	1,030.3			1,029.4	1,031.6
Return on Avg Shareholder Equity [1][2][3]		4.8%	4.4%			14.4%	13.5%
Effective Income Tax Rate [3]		37.25%	37.50%			36.85%	37.50%
LIFO Charge/(Credit)		24.2	12.7			69.8	55.2

INCOME STATEMENT SUMMARY		1st Qtr Ending: 11/30/2004			2nd Qtr Ending: 02/28/2005			6 Months Ending: 02/28/2005			3rd Qtr Ending: 05/31/2005			9 Months Ending: 05/31/2005
		% of	% to Sales		% of	% to Sales		% of	% to Sales		% of	% to Sales		% of	% to Sales
PRELIMINARY		Chg	2004	2003	Chg	2005	2004	Chg	2005	2004	Chg	2005	2004	Chg	2005	2004
Net Sales		13.4%	100.00	100.00	12.3%	100.00	100.00	12.8%	100.00	100.00	13.1%	100.00	100.00	12.9%	100.00	100.00
Costs and Deductions
	Cost of Sales	11.8%	72.61	73.63	11.0%	71.50	72.34	11.4%	72.03	72.95	11.6%	72.15	73.09	11.5%	72.07	72.99
	Selling, Occupancy & Admin [3]	16.6%	22.42	21.79	16.1%	21.48	20.77	16.4%	21.92	21.25	16.8%	21.96	21.26	16.5%	21.94	21.26
	Sub-Total	12.9%	95.03	95.42	12.2%	92.98	93.11	12.5%	93.95	94.20	12.8%	94.11	94.35	12.6%	94.01	94.25
Earnings Before Other Income		22.9%	4.97	4.58	14.4%	7.02	6.89	17.6%	6.05	5.80	17.8%	5.89	5.65	17.7%	5.99	5.75
	Net Other, Income(Expense)[1][2]	617.9%	0.20	0.03	-31.7%	0.10	0.17	61.5%	0.15	0.11	165.2%	0.16	0.07	87.7%	0.16	0.09
Earnings Before Taxes		27.1%	5.17	4.61	13.3%	7.12	7.06	18.3%	6.20	5.91	19.6%	6.05	5.72	18.8%	6.15	5.84
	Effective Income Tax Rate		35.72%	37.50%		37.25%	37.50%		36.64%	37.50%		37.25%	37.50%		36.85%	37.50%
Earnings After Taxes		30.7%	3.32	2.88	13.7%	4.47	4.41	20.0%	3.93	3.69	20.1%	3.79	3.57	20.0%	3.88	3.65
[1]	2004 Drug antitrust litigation settlements: 2nd Qtr - (2 Totaling) $12.7; 3rd Qtr - $3.0; 4th Qtr - $0.6
[2]	2005 Drug antitrust litigation settlements: 1st Qtr - $15.0; 2nd Qtr - $4.7; 3rd Qtr - $6.6
[3]	Prior period amounts have been restated for the accounting of leases consistent with our March 21st, 2005 press release and 8-K.

								PRELIMINARY						CONTINUING OPERATIONS
		Total	Percent Change in Sales				Key Operating Ratios			Other Items			Company Income and Return on Sales
		Company	Total	Drug Stores			Gross		Op	Net	Other		Pre-Tax	Tax	Income After Taxes
Period		Sales	Co	Total	Comp	Est	Profit	SGA	Income	Interest	Income	% Sales	% Sales	Rate	Amount	% Sales	% Chg
		Amounts in Millions							Other Income: Antitrust Litigation Settlements
04-Q1		8,720.8	16.5	16.5	11.9	10.4	26.37	21.79	4.58	2.8	0.0	0.03	4.61	37.50	251.5	2.88	9.9
04-Q2		9,782.2	15.8	15.8	11.5	9.9	27.66	20.77	6.89	4.0	12.7	0.17	7.06	37.50	431.6	4.41	17.0
04-Q3		9,578.5	15.0	15.0	10.4	8.7	26.91	21.26	5.65	3.6	3.0	0.07	5.72	37.50	342.3	3.57	16.4
04-Q4		9,426.7	14.3	14.3	9.7	7.8	27.74	22.31	5.43	6.9	0.6	0.08	5.51	37.50	324.4	3.44	18.7
2004		37,508.2	15.4	15.4	10.9	9.3	27.19	21.52	5.67	17.3	16.3	0.09	5.76	37.50	1,349.8	3.60	15.9
		Amounts in Millions							Other Income: Antitrust Litigation Settlements
05-Q1		9,889.1	13.4	13.4	9.4	7.9	27.39	22.42	4.97	5.1	15.0	0.20	5.17	35.72	328.6	3.32	30.7
05-Q2		10,987.0	12.3	12.3	7.7	6.2	28.50	21.48	7.02	6.7	4.7	0.10	7.12	37.25	490.9	4.47	13.7
05-Q3		10,830.6	13.1	13.1	8.7	7.0	27.85	21.96	5.89	10.9	6.6	0.16	6.05	37.25	411.0	3.79	20.1
05-Q4
2005		31,706.7	12.9	12.9	8.6	7.1	27.93	21.94	5.99	22.7	26.3	0.16	6.15	36.85	1,230.5	3.88	20.0
	Prior period amounts have been restated for the accounting of leases consistent with our March 21st, 2005 press release and 8-K.

							STORE COUNT AND MONTHLY SALES INCREASES
								PRELIMINARY
Number of Drug Stores
					Six				Nine				Total
		1st Qtr	2nd Qtr		Mos		3rd Qtr		Mos		4th Qtr		Year
2003-04	Start of Period	4,227	4,291		4,227		4,336		4,227		4,414		4,227
	Opened	85	55		140		88		228		208		436
	Relocation	-20	-6		-26		-9		-35		-34		-69
	Closed	-1	-4		-5		-1		-6		-6		-12
	End of Period	4,291	4,336		4,336		4,414		4,414		4,582		4,582
2004-05	Start of Period	4,582	4,680		4,582		4,738		4,582
	Opened	111	67		178		85		263
	Relocation	-10	-7		-17		-17		-34
	Closed	-3	-2		-5		-1		-6
	End of Period	4,680	4,738		4,738		4,805		4,805
Monthly Sales Percent Increases
		Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Year
	2003-04	17.8	16.6	15.3	17.7	13.2	16.3	17.4	15.1	12.6	15.5	13.4	14.1	15.4
	2004-05	13.2	11.8	15.2	8.9	14.6	14.3	16.1	9.6	13.4				12.9

						PRELIMINARY
INTERIM HIGHLIGHTS					Six		Nine		Total
		1st Qtr	2nd Qtr		Mos	3rd Qtr	Mos	4th Qtr	Year
Total Sales	2003-04	8,720.8	9,782.2		18,503.0	9,578.5	28,081.5	9,426.7	37,508.2
(In Millions)	2004-05	9,889.1	10,987.0		20,876.1	10,830.6	31,706.7
% of Increase	2003-04	16.5%	15.8%		16.1%	15.0%	15.8%	14.3%	15.4%
	2004-05	13.4%	12.3%		12.8%	13.1%	12.9%
Net Income	2003-04	251.5	431.6		683.1	342.3	1,025.4	324.4	1,349.8
[1][2]	2004-05	328.6	490.9		819.5	411.0	1,230.5
(In Millions)
% of Increase	2003-04	9.9%	17.0%		14.3%	16.4%	15.0%	18.7%	15.9%
	2004-05	30.7%	13.7%		20.0%	20.1%	20.0%
Diluted [1][2]
Earnings Per Share	2003-04	$ 0.24	$ 0.42		$ 0.66	$ 0.33	$ 0.99	$ 0.32	$ 1.31
Before Drug Litigation		$ 0.24	$ 0.41		$ 0.65	$ 0.33	$ 0.98	$ 0.32	$ 1.30
	2004-05	$ 0.32	$ 0.48		$ 0.80	$ 0.40	$ 1.20
Before Drug Litigation		$ 0.31	$ 0.47		$ 0.78	$ 0.40	$ 1.18
	[1] Antitrust Litigations		2004		2005
		1st Qtr			15.0
* Two settlements		2nd Qtr	12.7	*	4.7
		3rd Qtr	3.0		6.6
		4th Qtr	0.6
[2] Prior period amounts have been restated for the accounting of leases consistent with our March 21st, 2005 press release and 8-K.

							PRELIMINARY
CONSOLIDATED BALANCE SHEET [1]			May 31	May 31				May 31	May 31
			2005	2004				2005	2004
Current Assets			(Amounts in Millions)		Current Liabilities
	Cash & Equivalents		541.2	637.1		Short Term Borrowings		0.0	0.0
	Short Term Investments Available For Sale		829.0	1,221.5		Trade Accounts Payable		2,827.1	2,636.9
	Accounts Receivable, Less Allowance		1,515.7	1,298.3		Other Current Liabilities		1,454.4	1,329.2
	Inventories		5,204.6	4,359.8		Income Taxes		106.5	139.4
	Other Current Assets		191.9	152.6			Total Current Liabilities	4,388.0	4,105.5
		Total Current Assets	8,282.4	7,669.3
Non-Current Assets					Non-Current Liabilities
	Property and Equipment		5,931.5	5,255.4		Deferred Income Taxes		271.8	227.4
	Other Non-Current Assets		127.7	111.0		Other Non-Current Liabilities		965.3	783.3
		Total Non-Current Assets	6,059.2	5,366.4			Total Non-Current Liabilities	1,237.1	1,010.7
					Total Liabilities			5,625.1	5,116.2
					Shareholder Equity			8,716.5	7,919.5
Total Assets			14,341.6	13,035.7	Total Liabilities & Equity			14,341.6	13,035.7
STATEMENT OF CASH FLOWS [1]			May 31	May 31				May 31	May 31
			2005	2004				2005	2004
Cash Flows From Operating Activities			(Amounts in Millions)		Provided/(Used) by Invest & Finance
	Net Income		1,230.5	1,025.4		Property, Plant & Equipment		(855.9)	(630.9)
	Depreciation & Amortization		352.2	288.2		Employee Stock Plan Proceeds		137.6	101.3
	Inc Tax Savings From Employee Stock Plans		25.4	25.6		Property & Equip Disp and Other		10.8	16.1
	Deferred Income Taxes		(25.4)	23.4		Cash Dividends		(161.1)	(132.6)
	Other		43.8	33.6		Stock Purchases		(644.7)	(184.6)
						Net Proceeds from Corp Owned Life Ins		8.5	8.6
						Other		24.3	(11.3)
						Short Term Investments Available For Sale		437.8	(1,217.1)
Changes in Current Assets & Liabilities:
	Inventory		(466.0)	(157.2)
	Trade Accounts Payable		185.6	229.0
	Accrued Expenses & Liabilities		42.5	151.1
	Income Taxes		40.5	33.5	Provided/(Used) by Invest & Finance			(1,042.7)	(2,050.5)
	Accounts Receivable		(344.3)	(300.3)
	Insurance Reserve		71.1	84.5		Changes In Cash & Equivalents		97.2	(630.9)
	Other Current Assets		(16.0)	(17.2)		Beginning Cash & Equivalents		444.0	1,268.0
Provided/(Used) for Operating Activities			1,139.9	1,419.6	Cash & Equivalents at End of Period			541.2	637.1
[1] Prior period amounts have been restated for the accounting of leases consistent with our March 21st, 2005 press release and 8-K.